Literature DB >> 9047157

Hyperacute lung rejection in a pig-to-human transplant model: the role of anti-pig antibody and complement.

R N Pierson1, W Kasper-Konig, D N Tew, V K Young, J J Dunning, J Horsley, N R Carey, J Wallwork, D J White.   

Abstract

BACKGROUND: The physiology of hyperacute rejection of pig lung by human blood and the role of antispecies antibody and complement in this phenomenon have not previously been characterized.
METHODS: Human blood was perfused through an ex vivo pig heart-lung preparation. In the treatment groups, blood was either unmodified or modified to deplete alternative pathway complement (heat treatment), anti-pig antibody, or both. Control experiments were performed with unmodified and heat-treated pig blood. Physiologic parameters, organ survival, and immunohistology were the primary outcome measures assessed.
RESULTS: Pig lung was consistently damaged by human blood within 45 min (median 20 min), as evidenced by elevated pulmonary vascular resistance and parenchymal injury. Immunohistologic studies of perfused lungs showed prominent deposition of IgM and classical pathway component, C4, and weaker deposition of alternative pathway component, properdin. Heat treatment did not impede the rise in pulmonary vascular resistance or significantly prolong survival. Depletion of anti-pig antibody prolonged survival (median 90 min) and attenuated the rise in pulmonary vascular resistance. Antibody absorption, combined with heat treatment of plasma, prevented the elevation in pulmonary vascular resistance and yielded median graft survival (210 min) similar to pig blood perfusion (approximately 240 min).
CONCLUSIONS: These results show that elevated pulmonary vascular resistance and pulmonary parenchymal injury are mediated at least in part by antispecies antibody and heat-sensitive pathways. They are consistent with the hypothesis that complement activation contributes significantly to acute lung damage in the pig-to-human species combination.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9047157     DOI: 10.1097/00007890-199702270-00019

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  6 in total

Review 1.  Antibody-mediated xenograft injury: mechanisms and protective strategies.

Authors:  Richard N Pierson
Journal:  Transpl Immunol       Date:  2009-04-17       Impact factor: 1.708

2.  Absence of Gal epitope prolongs survival of swine lungs in an ex vivo model of hyperacute rejection.

Authors:  Bao-Ngoc H Nguyen; Agnes M Azimzadeh; Carsten Schroeder; Thomas Buddensick; Tianshu Zhang; Amal Laaris; Megan Cochrane; Henk-Jan Schuurman; David H Sachs; James S Allan; Richard N Pierson
Journal:  Xenotransplantation       Date:  2011 Mar-Apr       Impact factor: 3.907

3.  Immune complex formation after xenotransplantation : evidence of type III as well as type II immune reactions provide clues to pathophysiology.

Authors:  Z E Holzknecht; S Coombes; B A Blocher; T B Plummer; M Bustos; C L Lau; R D Davis; J L Platt
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

Review 4.  Clinical lung xenotransplantation--what donor genetic modifications may be necessary?

Authors:  David K C Cooper; Burcin Ekser; Christopher Burlak; Mohamed Ezzelarab; Hidetaka Hara; Leela Paris; A Joseph Tector; Carol Phelps; Agnes M Azimzadeh; David Ayares; Simon C Robson; Richard N Pierson
Journal:  Xenotransplantation       Date:  2012 May-Jun       Impact factor: 3.907

Review 5.  Lung xenotransplantation: recent progress and current status.

Authors:  Donald G Harris; Kevin J Quinn; Siamak Dahi; Lars Burdorf; Agnes M Azimzadeh; Richard N Pierson
Journal:  Xenotransplantation       Date:  2014-07-05       Impact factor: 3.907

6.  64-channel multi-detector row CT angiographic evaluation of the micropigs for potential living donor lung transplantation.

Authors:  Woong Yoon; Jung Min Ryu; Min Young Lee; Yong Ju Moon; Sang Hun Lee; Jae Hong Park; Seung Pil Yun; Min Woo Jang; Sung Su Park; Ho Jae Han
Journal:  J Vet Sci       Date:  2010-09       Impact factor: 1.672

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.